-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 17, Fosun Pharma issued an announcement stating that its controlling subsidiary Hanlius Pharmaceuticals had received the "Drug Supplementary Application for Trastuzumab for Injection (trade name: Hanquyou®) issued by the National Medical Products Administration.
The drug is a monoclonal antibody biosimilar independently developed by the Group (ie the company and its holding subsidiaries/units, the same below).
As of the date of this announcement, the trastuzumab approved for marketing in China includes Roche's Herceptin® and Hanlin Pharmaceutical's Hantrauyou®
As of July 2021, the Group’s current cumulative R&D investment for the drug is approximately RMB 979.